TIBSOVO (ivosidenib tablets), for oral use. Initial U.S. Approval: 2018

Ivosidenib, sold under the brand name Tibsovo, is a medication for the treatment of acute myeloid leukemia (AML). It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. The drug is being developed by Agios Pharmaceuticals and is in phase III clinical trials.[when?] The U.S. Food and Drug Administration (FDA) awarded orphan drug designation for acute myeloid leukemia and cholangiocarcinoma.
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
In 2018, ivosidenib was approved in the United States for relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation and is presently[when?] in a phase III clinical trial for cholangiocarcinoma with an IDH1 mutation.
In 2019, ivosidenib was approved in the United States for newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.

HOW AND WHERE TO BUY ivosidenib tablets?

You can order ivosidenib tablets direct from Medvitaz Pharma Solutions if the drug has not been approved or is not available in your country. We help you to get genuine, affordable and assurance of delivery. To get best retail price/cost of ivosidenib tablets in India, Call 8750295029 or Email [email protected]. FDA approved drugs of Australia, Canada, Delhi, EU, India, New Zealand, Singapore, Switzerland, Turkey & USA.